Skip to main content

COVID-19: A USCAP Miniseries - A USCAP Learning Tool

Original release date: October 5, 2020
Access to this course expires on:  August 25, 2023 at 11:59 PM Pacific Time
CME 3.5

Course Description
Living at the (cutting) edge, USCAP pathologists are eager to fortify their knowledge and understanding of emerging information about the COVID-19 pandemic from the perspective of laboratory medicine, research and anatomic findings. The first episode of a three-part series explores the role of laboratory medicine in serology testing and plasma therapy for the COVID-19 pandemic. The second episode concentrates on molecular diagnostics for SARS-CoV-2, the virus that causes COVID-19, addressing challenges of testing, results interpretation and utility of clinical decision support to aid in appropriate test utilization. The final episode describes the procedure for COVID-19 autopsies at a leading academic institution, including gross and microscopic pathologic findings and the clinical and basic research efforts underway in making use of the autopsy material.

Target Audience
Practicing academic and community pathologists, and pathologists-in-training

Learning Objectives
Upon completion of this educational activity, learners will be able to:
  • Describe the role of antibody testing and convalescent plasma therapy in the COVID-19 pandemic
  • Reference important articles that have changed our understanding of SARS-CoV-2 antibody testing and plasma therapy
  • Evaluate various molecular platforms for detection of SARS-CoV-2 viral RNA
  • Identify sources of false negative SARS-CoV-2 results
  • Describe the primary challenges facing the clinical lab in implementation of assays to detect SARS-CoV-2
  • Describe the procedure for COVID-19 autopsies at Brigham and Women’s Hospitalwho, what, where, when, why, how
  • Describe the autopsy experience of COVID-19 patients including gross and microscopic pathologic findings
  • Describe some of the clinical and basic research efforts underway

 Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 3.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: Neil Anderson, MD, Scientific Advisory Board, Diasorin Molecular

The following faculty reported no relevant financial relationships: Melissa Cushing, MD, Bijal Parikh, MD, PhD, and Robert F. Padera, MD, PhD

Enter the promo code  CovidSeriesDiscount at checkout to get $29 off this course!